3 news items
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
GLYC
29 May 24
differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GLYC
6 May 24
in 2023. These increases were due to raw material acquisition costs for future manufacturing batches
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
GLYC
27 Mar 24
and impact of the company's drug candidates. Actual results may differ materially from those described in these forward-looking statements. For a further
- Prev
- 1
- Next